Skip to content

Study · Randomized controlled trial · n = 51 · 2018

4 results

Effect of chronic liraglutide therapy and its withdrawal on time to postchallenge peak glucose in type 2 diabetes.

Tran S, Kramer CK, Zinman B, Choi H, Retnakaran R

American journal of physiology. Endocrinology and metabolism28 Nov 2017Cited by 15 (Europe PMC)

PMID29183873 (opens in a new tab)DOI10.1152/ajpendo.00374.2017 (opens in a new tab)PepBankPUB-29183873
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with early type 2 diabetes, 65.4% on liraglutide had shifted to an earlier peak glucose by 12 weeks versus 36% on placebo, a difference that was not significant.

    In plain wordsIn adults with early type 2 diabetes, liraglutide did not clearly shift the time of peak blood sugar earlier than placebo at 12 weeks.

    Peptide
    Liraglutide
    Outcome
    No significant changeShift to earlier peak glucose at 12 weeks
    Study

    n = 51

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Shifted to earlier peak
    65.4%
    liraglutide at 12 weeks

    Source sentences

    Summary
    By 12 wk, 65.4% of the liraglutide arm had shifted to an earlier peak (vs. 36% on placebo; P = 0.19), with little change thereafter at 24, 36, and 48 wk.
    1 context sentence
    Summary · context
    In this secondary analysis of a double-blind placebo-controlled trial, 51 patients with T2DM of 2.6 ± 1.9 yr duration were randomized to daily subcutaneous liraglutide or placebo injection for 48 wk, with oral glucose tolerance test (OGTT) performed every 12 wk while on therapy and after a 2-wk washout.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with early type 2 diabetes, 57.7% of those who had been on liraglutide reverted to a later peak glucose after a 2-week washout versus 4.5% on placebo.

    In plain wordsIn adults with early type 2 diabetes, stopping liraglutide for 2 weeks sent peak blood sugar back to a later time, more than with placebo.

    Peptide
    Liraglutide
    Outcome
    IncreaseReversion to later peak glucose after 2-week washout
    Study

    n = 51

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 48 weeksAs given in this study (human).

    Measurements

    Reverted to later peak
    57.7%
    liraglutide after washout

    Source sentences

    Summary
    After the 2-wk washout, however, 57.7% of those who had been on liraglutide reverted to a later peak (vs. 4.5% on placebo; P < 0.001).
    1 context sentence
    Summary · context
    In this secondary analysis of a double-blind placebo-controlled trial, 51 patients with T2DM of 2.6 ± 1.9 yr duration were randomized to daily subcutaneous liraglutide or placebo injection for 48 wk, with oral glucose tolerance test (OGTT) performed every 12 wk while on therapy and after a 2-wk washout.
  3. 03HumanRandomized controlled trialMechanism

    In adults with early type 2 diabetes, the shift to a later peak glucose after liraglutide washout was associated with declining beta-cell function.

    In plain wordsIn adults with early type 2 diabetes, after liraglutide was stopped, the later blood sugar peak was linked to worse beta-cell function.

    Peptide
    Liraglutide
    Outcome
    DecreaseBeta-cell function after liraglutide washout
    Study

    n = 51

    Comparator
    Placebo
    Outcome group
    Glycemic control · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneous · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    This shift was associated with declining β-cell function ( P = 0.001)
    1 context sentence
    Summary · context
    In this secondary analysis of a double-blind placebo-controlled trial, 51 patients with T2DM of 2.6 ± 1.9 yr duration were randomized to daily subcutaneous liraglutide or placebo injection for 48 wk, with oral glucose tolerance test (OGTT) performed every 12 wk while on therapy and after a 2-wk washout.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with early type 2 diabetes, 2-hour blood glucose at washout was higher in the liraglutide arm than with placebo.

    In plain wordsIn adults with early type 2 diabetes, blood sugar 2 hours after a sugar drink was higher after stopping liraglutide than after placebo.

    Peptide
    Liraglutide
    Outcome
    Increase2-hour blood glucose at washout
    Study

    n = 51

    Comparator
    Placebo
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 48 weeksAs given in this study (human).

    Source sentences

    Summary
    resulting in higher 2-h blood glucose at washout in the liraglutide arm compared with placebo ( P = 0.001).
    1 context sentence
    Summary · context
    In this secondary analysis of a double-blind placebo-controlled trial, 51 patients with T2DM of 2.6 ± 1.9 yr duration were randomized to daily subcutaneous liraglutide or placebo injection for 48 wk, with oral glucose tolerance test (OGTT) performed every 12 wk while on therapy and after a 2-wk washout.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.